Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 20/20 | 0.62 |
| ▸ | SLC6A4 | P31645 | 20/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 18/20 | 0.62 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5836497 | 0.83 | HTR2A (0.68) | HTR2ASLC6A4KCNH2SLC6A2SLC6A3 | |
| SCHEMBL7188327 | 0.82 | HTR2A (0.69) | HTR2ASLC6A4KCNH2 | |
| SCHEMBL5836789 | 0.80 | HTR2A (0.67) | HTR2ASLC6A4KCNH2SLC6A2SLC6A3 | |
| SCHEMBL7642609 | 0.79 | HTR2A (0.74) | HTR2ASLC6A4KCNH2 | |
| SCHEMBL5837104 | 0.78 | SLC6A4 (0.74) | HTR2ASLC6A4KCNH2SLC6A2SLC6A3 | |
| SCHEMBL5838185 | 0.76 | HTR2A (1.00) | HTR2ASLC6A4KCNH2 | |
| Hydrochloric Acid SCHEMBL5709638 | 0.75 | HTR2A (0.97) | HTR2ASLC6A4KCNH2 | |
| SCHEMBL5314078 | 0.75 | HTR2A (0.71) | HTR2ASLC6A4KCNH2SLC6A2SLC6A3 | |
| SCHEMBL6056311 | 0.74 | HTR2A (0.76) | HTR2ASLC6A4KCNH2 | |
| SCHEMBL5836771 | 0.72 | HTR2A (0.54) | HTR2ASLC6A4KCNH2SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030130322-A1 | Biaryl ether derivative as opiod antagonist | PFIZER INC. | 2003-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130322-A1 | Biaryl ether derivative as opiod antagonist | OPRM1, OPRD1, OPRK1 | HTR2A 29/4885SLC6A4 40/4885KCNH2 2000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.